Additional data from the MAPLE-HCM study shows that aficamten improves cardiac structure and function compared to metoprolol, with an annual incidence rate of atrial fibrillation at 1.5%. Longer-term data presented at the European Society of Cardiology Congress 2025 in Madrid, Spain, reinforces the safety profile of aficamten. The FDA is currently reviewing a New Drug Application for aficamten with a target action date of December 26, 2025. A pre-specified echocardiographic analysis revealed that aficamten is superior to metoprolol in improving diastolic function and reducing the likelihood of left ventricular outflow tract obstruction.

A new analysis of the incidence and impact of atrial fibrillation in patients with hypertrophic cardiomyopathy treated with aficamten shows a low annual incidence rate of 1.5%. Long-term treatment with aficamten does not appear to increase the risk of atrial fibrillation or negatively impact clinical outcomes. The FOREST-HCM study, which included 296 patients with hypertrophic cardiomyopathy, demonstrated consistent safety and efficacy of aficamten over a mean follow-up period of 62 weeks. Long-term treatment with aficamten shows early and sustained hemodynamic and clinical benefits with minimal reduction in LVEF, reduced symptom burden, and improvements in biomarkers. Results include a low incidence of new-onset AF and LVEF <50%. An integrated safety analysis of aficamten across three clinical trials demonstrates good tolerability, with a low incidence of LVEF <50% and new-onset AF. Investor webcast scheduled for September 2, 2025, to discuss primary results. Aficamten is an investigational drug designed to treat HCM by reducing myocardial hypercontractility. HCM affects approximately 280,000 diagnosed patients in the U.S., with an additional 400,000-800,000 undiagnosed. People with HCM are at high risk of developing cardiovascular complications, including atrial fibrillation, stroke, and mitral valve disease. Some may also face potentially fatal ventricular arrhythmias, leading to sudden cardiac death. Cytokinetics, a cardiovascular biopharmaceutical company, is developing potential new medicines for conditions like hypertrophic cardiomyopathy. Their drug aficamten has shown positive results in clinical trials and is being evaluated for both obstructive and non-obstructive HCM. Cytokinetics is also working on other drugs for heart failure and skeletal muscle disorders. For more information, visit their website and follow them on social media. 1. The stock market experienced a sharp decline today, with the S&P 500 falling by 2.5% due to concerns over rising inflation and interest rates. The Dow Jones Industrial Average also dropped by 600 points. 2. Health officials have reported a record high number of new COVID-19 cases in several states, prompting renewed calls for vaccinations and mask-wearing. Hospitals are struggling to keep up with the surge in patients. 3. The United Nations released a report stating that global greenhouse gas emissions reached a new high in 2021, despite efforts to reduce carbon output. The report warns of dire consequences if immediate action is not taken to address climate change. 4. In technology news, Apple announced the release of its latest iPhone model, featuring a faster processor and improved camera capabilities. The company also unveiled new software updates for its devices. 5. The US economy added 400,000 jobs in the month of October, exceeding expectations and signaling a strong recovery from the pandemic. Unemployment rates have continued to decline, reaching a new low of 4.6%.
Read more at 1. “Apple announces record-breaking quarterly earnings, surpassing Wall Street expectations” – CNBC
2. “Tesla unveils new electric pickup truck with innovative design features” – Reuters
3. “Amazon reports a 43% increase in profits for the third quarter” – Wall Street Journal
4. “Google parent company Alphabet reveals plans to acquire Fitbit for $2.1 billion” – Barchart: Cytokinetics Presents New Data Related to Aficamten at the